gastric disease
Conditions
Interventions
group 1:SLC22A1 1022CC
group 3:SLC22A1 1022TT
group 2:SLC22A1 1022CT
group 4:SLC22A1 848CC
group 5:SLC22A1 848CT
group 6:SLC22A1 848TT
Sponsors
Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
Eligibility
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Male, 18-40 years of age (including boundary value); subjects body mass index (BMI): 19-26 (including boundary value); According to the medical examination, vital signs, electrocardiogram and clinical laboratory result, participants are healthy, and the inspection was taken 1 week before the drug administration; subjects are able to read and understand the contents of the informed consent, and sign the informed consent before any research related operations; subjects are not taken any other drugs two weeks before the test.
Exclusion criteria
Exclusion criteria: Subjects with arrhythmia, bronchial or cardiovascular disease history, diabetes, thyrotoxicosis, Parkinson's syndrome, or any other disease or physiology that can interference test results; with disease that can affect drug absorption or metabolic disease of the gastrointestinal tract; have drug abuse history or positive urine drug test results in the past one year; used other medicines within 14 days before the test; participated in other drug experiments within 30 days before the test; Serious blood loss or donation (500 ml) within 3 months before the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood drug concentratio; | — |
Countries
China
Contacts
Public ContactLingling Dai
Outcome results
None listed